



Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting

August 26, 2020

Following the ACIP presentation today at 10:30 a.m. ET, management will host a conference call to be held today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 26, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced it is presenting at the Centers for Disease Control and Prevention's [Advisory Committee on Immunization Practices](#) (ACIP) August Meeting today. The live presentation can be [viewed online here](#).

This presentation will include new interim safety and immunogenicity data from the cohorts of older adults in the NIH-led Phase 1 study of mRNA-1273, Moderna's vaccine candidate against COVID-19. The ACIP presentation slides will be available under "[Events and Presentations](#)" in the Investors section of the Moderna website.

Conference Call and Webcast Information

Following the ACIP presentation of 10:30 ET, Moderna will host a live conference call and webcast at 4:30 p.m. ET on Wednesday, August 26, 2020. To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 2444108. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna's website approximately two hours after the conference call.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200826005466/en/): <https://www.businesswire.com/news/home/20200826005466/en/>

Moderna

Media:

Colleen Hussey
Senior Manager, Corporate Communications
203-470-5620
Colleen.Hussey@modernatx.com

Investors:

Lavina Talukdar
Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.